Humanized anti-tau(pS422) antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-10822402-B2
Application number	US-201715832176-A
Country	US
Kind code	B2
Filing date	Dec 5, 2017
Priority date	Jun 24, 2015
Publication date	Nov 3, 2020
Grant date	Nov 3, 2020

Abstract

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

First claim

The invention claimed is:

1. A humanized bi-specific antibody that specifically binds to human Tau(pS422) and a human transferrin receptor antigen, wherein the antibody comprises
(i) a first binding site comprising
in the heavy chain variable domain the HVRs of SEQ ID NO: 08, 09 and 10, and in the light chain variable domain
the HVRs of SEQ ID NO: 71, 73 and 15;
the HVRs of SEQ ID NO: 70, 72 and 15; or
the HVRs of SEQ ID NO: 12, 14 and 74; and

(ii) a second binding site comprising
a heavy chain variable domain of SEQ ID NO: 82 and a light chain variable domain of SEQ ID NO: 85;
a heavy chain variable domain of SEQ ID NO: 83 and a light chain variable domain of SEQ ID NO: 85; or
a heavy chain variable domain of SEQ ID NO: 84 and a light chain variable domain of SEQ ID NO: 85.

2. The humanized bi-specific antibody according to claim 1 , comprising
a) a heavy chain variable domain of SEQ ID NO: 65 and a light chain variable domain of SEQ ID NO: 67;
b) a heavy chain variable domain of SEQ ID NO: 65 and a light chain variable domain of SEQ ID NO: 66; or
c) a heavy chain variable domain of SEQ ID NO: 65 and a light chain variable domain of SEQ ID NO: 68.

3. The humanized bi-specific antibody according to claim 1 , wherein the antibody is effector function silent.

4. The humanized bi-specific antibody according to claim 1 , wherein the antibody
i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO: 03, and/or
ii) does not bind to full length human Tau (SEQ ID NO: 01) at 1 μg/mL, and/or
iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), and/or
iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02).

5. The humanized bi-specific antibody according to claim 1 , wherein the antibody has an EC 50 value for
a) the human Tau(pS422) fragment that has the amino acid sequence of SEQ ID NO: 03 of 6 ng/mL or less, and/or
b) the full length human Tau(pS422) that has the amino acid sequence of SEQ ID NO: 02 of 4.5 ng/mL or less, and/or
c) aggregates of human Tau (pS422) that has the amino acid sequence of SEQ ID NO: 02 of 30 ng/mL or less, and/or
d) the human Tau that has the amino acid sequence of SEQ ID NO: 01 and that has the amino acid mutation S422A of 125 ng/mL or less.

6. The humanized bi-specific antibody according to claim 1 , wherein the antibody specifically binds to human Tau(pS422) (SEQ ID NO: 02) and does not bind to human Tau (SEQ ID NO: 01).

7. The humanized bi-specific antibody according to claim 1 , wherein the antibody is
a) a full length antibody of the human subclass IgG1;
b) a full length antibody of the human subclass IgG4;
c) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G;
d) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G;
e) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain; or
f) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain.

8. A pharmaceutical formulation comprising the humanized bi-specific antibody according to claim 1 and optionally a pharmaceutically acceptable carrier.

9. A method of treating a subject suffering from Alzheimer's Disease, the method comprising administering to the subject an effective amount of a humanized bi-specific antibody according to claim 1 .

10. A method of treating a subject suffering from prodromal Alzheimer's Disease, the method comprising administering to the subject an effective amount of a humanized bi-specific antibody according to claim 1 .

11. A method for reducing Tau(pS422) induced neurodegeneration in a subject comprising administering to the subject an effective amount of a humanized bi-specific antibody according to claim 1 .

12. A method of treatment comprising administering a humanized bi-specific antibody according to claim 1 for treating Alzheimer's disease, for treating prodromal Alzheimer's disease, for treating mild Alzheimer's disease, for reducing Tau(pS422)-induced neurodegeneration, for maintaining cognition and function, for slowing the rate of cognitive and functional decline, or for slowing down the rate of neurofibrillary tangle accumulation.

Assignees

• Hoffmann La Roche

Inventors

• Dengl Stefan
• Emrich Thomas
• Georges Guy
• Goepfert Ulrich
• Grueninger Fiona
• Hugenmatter Adrian
• Jochner Anton
• Kettenberger Hubert
• Moelleken Joerg
• Moessner Ekkehard
• Mundigl Olaf
• Niewoehner Jens
• Schlothauer Tilman
• Molhoj Michael
• Brady Kevin

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title